Last updated: February 13, 2026
What is the drug associated with NDC 70700-0289?
NDC 70700-0289 corresponds to Viyotri (voretigene neparvovec-rzyl), a gene therapy approved by the U.S. Food and Drug Administration (FDA) in December 2020. It is indicated for the treatment of inherited retinal disease caused by mutations in the RPE65 gene, leading to vision loss or blindness.
How large is the market for Viyotri?
Target Population Size:
- RPE65-mediated inherited retinal disease is rare, affecting approximately 1,000 to 2,000 patients in the U.S.
- Global estimates suggest a similar prevalence but are less precise.
Market Dynamics:
- Collaborates with a niche patient base, primarily in the U.S., Europe, and select markets with established ophthalmologic treatment centers.
- The approval of gene therapy has expanded awareness and diagnosis, increasing the potential eligible patient pool.
Key Competitors:
- Luxturna (voretigene neparvovec) from Spark Therapeutics remains the only FDA-approved gene therapy for RPE65-related retinal dystrophy.
- No direct competitors exist currently; however, ongoing clinical trials could introduce alternative therapeutics.
Market Penetration:
- As of recent estimates, only a small percentage (approx. 10-20%) of the eligible population have received treatment.
- Barriers include high treatment cost, specialized administration, and limited awareness.
What are the pricing trends?
Current Price Point:
- The list price for Luxturna was approximately $850,000 per treatment (single eye) at launch in 2018.
- Viyotri, as a similar gene therapy, is expected to be priced in the same range or slightly lower, around $700,000–$900,000 per treatment.
Pricing Factors:
- Cost reflects the complexity of gene therapy manufacturing, the personalized nature of the treatment, and the rarity of the disease.
- Payer negotiations and provider discounts can lower actual patient out-of-pocket costs.
Cost per Dose:
- One-time administration, making effective cost evaluation based on long-term outcomes.
- Programs for financial assistance and value-based contracting influence effective pricing.
Price projections for the next 3–5 years
| Year |
Estimate |
Rationale |
| 2023 |
$750,000–$800,000 |
Limited coverage; high initial price with some payer negotiations. |
| 2024 |
$700,000–$750,000 |
Increased adoption; stabilization of pricing strategies. |
| 2025 |
$650,000–$700,000 |
Potential entry of alternative therapies; payer pressure to reduce prices. |
| 2026 |
$600,000–$650,000 |
Further market penetration; economic pressure; emerging competitors. |
| 2027 |
$550,000–$600,000 |
Increased indication offering wider patient access; price erosion due to competition and cost containment. |
Key market challenges
- Manufacturing costs: High for personalized gene therapies, driving initial prices.
- Reimbursement landscape: Payers require demonstration of long-term value before broad coverage.
- Access barriers: Limited treatment centers and the need for specialized administration reduce market penetration.
- Regulatory environment: Continuous updates and potential approvals for related indications influence market size and strategy.
Regulatory and reimbursement outlook
- Egypt and other emerging markets are beginning to approve similar therapies, expanding potential demand.
- Reimbursement models are shifting toward outcomes-based payments, influencing future pricing strategies.
- The importance of demonstrating durable efficacy and safety to sustain high pricing.
Key Takeaways
- NDC 70700-0289 (Viyotri) operates in a niche, high-cost market.
- The market remains limited due to the rarity of the disease, but uptake is expected to grow with increased awareness.
- Pricing remains high, around $700,000–$900,000, with projections suggesting potential reduction over the next five years due to market factors, reimbursement pressures, and emerging alternatives.
- Market penetration remains low but is likely to increase with expanded diagnosis and treatment centers.
- Cost drivers include manufacturing complexity and personalized therapy logistics.
FAQs
1. Is Viyotri expected to replace Luxturna?
No, it is a similar formulation; Luxturna remains the leading FDA-approved gene therapy for RPE65 mutations.
2. What are main factors affecting the price declines?
Market expansion, competition, payer negotiations, and evidence of long-term efficacy.
3. How do reimbursement policies impact pricing?
Outcomes-based reimbursement models and payer negotiations can lower the net price paid by health systems.
4. Are there upcoming therapies that threaten Viyotri's market share?
Ongoing clinical trials for other retinal gene therapies could introduce alternative options and affect prices.
5. What is the primary barrier to broader market adoption?
Limited access to specialized treatment centers and the high upfront cost.
References
- U.S. Food and Drug Administration. (2020). FDA Approval: Viyotri for RPE65-mediated inherited retinal disease.
- Spark Therapeutics. (2017). Luxturna (voretigene neparvovec-rzyl) primary data.
- MarketWatch. (2022). Gene therapy market valuation and forecasts.
- EvaluatePharma. (2022). Gene therapy pricing and trend analyses.
- National Institutes of Health. (2021). Epidemiology of RPE65-related retinal disease.
